Market-Focused Drug Development
The challenges of integrated drug development
At Niven Biopharma, we believe that market potential should form the basis for developing new drugs and therapies. From this starting point, multiple interrelated functions must work seamlessly together so that the therapy can be brought to patients as quickly as possible.
With high risks of failure, there is significant pressure to make the best decisions at each stage of the development journey and to secure return on investment.
​
Drug and therapeutic companies often struggle to get this right, as they may:
-
Have poor coordination between functional silos
-
Have conflicting priorities or different visions of what is considered successful
-
Give less weight to aspects they are not familiar with
-
Adopt a short-term focus on value, rather than on the longer term
Our approach: Driving asset value through a market back perspective
Niven Biopharma helps companies optimise company and asset value by focusing on integrated drug development challenges.
We do this by first adopting a market back view of what needs to be carried out to be successful, considering the needs of patients, prescribers, payers and other health system stakeholders.
Once this is clear, we lead a cross functional team comprised of the right experts to resolve the problem, identify synergies and ways to optimize value. Usually, a mixture of internal and external expertise is best. These different views are consolidated into a single plan and scheduled for delivery.
We provide advice and project management support, focusing on achievement of milestones, risk management, effective communication, governance and reporting
Services
We specialise in services that require cross-functional working in drug development. Examples of our offering are illustrated below, however if you have a specific challenge not covered here please do get in touch and we would be happy to explore how we can help you. We typically work either in an advisory capacity or as a project/programme lead.
About
Doug Niven | Asset Leadership
Doug Niven has over 20 years professional experience in research, health and life science sectors. He has worked extensively with big pharma, biotechs as well as financial investors and med tech companies. During this time he has supported the development and commercialisation of over 20 different drugs/therapies.
He brings extensive experience in working across multiple therapeutic areas including rare diseases, inflammation and immunology, neurology and oncology. He has also worked on assets with different treatment modalities including small molecules, biologics, medical devices and digital therapeutics.
Biopharma over coffee blog
Check out our blog Biopharma Over Coffee in which we cover new and innovative developments in biotech, pharma and the markets. Each article perfect to read over a cup of coffee. Below are links to several recent articles.